Study of the Effects and Mechanisms of Yeast Postbiotics on Persistent Allergic Rhinitis Symptoms

NCT07079748 · tracked via the Priya Life Science China tracker

Sponsor

LanZhou University

Phase

Not applicable

Started

2025-07-25

Last updated

2025-07-23

Condition(s) studied

Allergic Rhinitis

Investigational drug(s) / intervention(s)

Yeast PostbioticsPlacebo

Yeast Postbiotics: Participants in the intervention group will take two capsules of yeast postbiotics daily after meals, with each capsule containing 250 mg of yeast postbiotics, along with maltodextrin and silicon dioxide.

Placebo: Participants in the placebo group will take an equal number of placebo capsules, identical in dosage form, taste, appearance, and packaging. The placebo contains only maltodextrin and a small amount of silicon dioxide. All participants will take two capsules once daily, swallowed with warm water after meals.

Study summary

This study is designed as a randomized, double-blind, placebo-controlled human intervention trial among university students with persistent allergic rhinitis (AR) symptoms. The aim is to evaluate the effectiveness of yeast postbiotics in alleviating persistent AR symptoms and to explore the potential mechanisms by which yeast postbiotics modulate the gut microbiota to improve AR-related outcomes. A stratified randomization method will be applied to assign participants into the yeast postbiotic group and the placebo group. Stratification will be based on(1) Sex (male/female), and (2) Physician-diagnosed AR status (yes/no, based on self-reported clinical history), ensuring comparability between the two groups. During the intervention period, participants in the yeast postbiotic group will take two capsules of yeast postbiotic supplements daily after meals, while the placebo group will take two placebo capsules, identical in appearance and composition except without the active ingredients. The total study duration is 15 weeks, including a 1-week run-in period, 12-week intervention, and 2-week follow-up after the intervention.

All participants will be asked to complete a daily nasal symptom score (TNSS) and report any adverse events. At week 0, week 4, and week 12, follow-up assessments will be conducted, including: symptom and quality-of-life questionnaires (e.g., VAS, RQLQ), dietary intake surveys, anthropometric measurements (height, weight, body fat percentage), and biological sample collection (including blood, urine, saliva, and feces). Additionally, saliva samples will be collected specifically at week 2 of the intervention to assess mucosal immune markers.

Eligibility

Sex

ALL

Min age

18 Years

Max age

35 Years

Healthy volunteers

Inclusion Criteria: 1. Aged between 18 and 35 years; 2. Meeting the symptom criteria for persistent allergic rhinitis (AR) as defined in the Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition): (1) Symptoms: Two or more of the following-paroxysmal sneezing, watery rhinorrhea, nasal itching, and nasal congestion-lasting continuously or cumulatively for at least 1 hour per day; ocular symptoms such as tearing, itching, and redness may also be present; (2) Persistent AR: Symptoms occur on ≥4 days per week and persist for ≥4 consecutive weeks; 3. No use of probiotics, prebiotics, synbiotics, antihistamines, corticosteroids, or immunosuppressants within 1 month prior to screening; 4. Willing and able to maintain usual physical activity levels and dietary patterns during the study; 5. Able and willing to sign the informed consent form voluntarily. Exclusion Criteria: 1. Use of antibiotics, osmotic laxatives (e.g., magnesium sulfate, lactulose), anthraquinone-containing agents (e.g., rhubarb, aloe, senna), or gastrointestinal motility-promoting drugs (e.g., metoclopramide, domperidone, cisapride) within 1 month prior to screening; 2. Diagnosed with non-allergic rhinitis (e.g., vasomotor rhinitis, infectious rhinitis, hormonal rhinitis, drug-induced rhinitis), or with nasal polyps, severe nasal septum deviation, cerebrospinal fluid rhinorrhea, or aspirin-exacerbated respiratory disease (AERD); 3. Patients with uncontrolled allergic comorbidities, including sinusitis, otitis media, allergic asthma, or atopic dermatitis; 4. History of serious gastrointestinal diseases (e.g., severe diarrhea, inflammatory bowel disease), or gastrointestinal endoscopy within the past month; 5. Diagnosed with congenital genetic disorders, primary immunodeficiency diseases, severe systemic illnesses, or malignancies; 6. Pregnant or lactating women, or women with plans to conceive during the study period.

Primary outcome measure(s)

Total Nasal Symptom Score (TNSS) — Through intervention completion (Week 0 to Week 12)
A scoring system to evaluate the severity of four nasal symptoms: nasal itching, sneezing, rhinorrhea, and nasal congestion. Each symptom is rated on a scale of 0 to 3, with a total score ranging from 0 to 12. Higher scores indicate more severe symptoms.

Trial sites (1)

Facility	City	Region	Status
School of Public Health, Lanzhou University	Lanzhou	Gansu

More LanZhou University trials in China

Recurrence After Gastric and Intestinal Polyp Resection Starting soon

Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing Starting soon

Probiotic Yogurt in Patients With Chronic Cholecystitis Starting soon

Evaluating the Safety and Efficacy of Drug-Coated Autoperfusion Balloons Versus Conventional Drug-Coated Balloons Guided by IVUS-OCT Multimodal Imaging for Treating Acute Myocardial Infarction: OPERA-AMI Study Starting soon

Enhanced Ward Rounds and Communication for Pre-procedural Anxiety in GI Endoscopy Patients Starting soon

Other trials for the same condition

Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR Starting soon

Sphenopalatine Ganglion Acupuncture for Allergic Rhinitis Starting soon

Intratonsillar Immunotherapy for Allergic Rhinitis Recruiting

Study on the Effect and Mechanism of Lupatadine Fumarate in the Treatment of Allergic Rhinitis Recruiting

The Effect of Oral Probiotics on Allergic Rhinitis Symptoms and the Quality of Life Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07079748 on ClinicalTrials.gov ↗ ← All trials in China